Keywords: GLP-1 receptor agonists; lixisentatide; natriuretic peptides; randomized controlled trial EN GLP-1 receptor agonists lixisentatide natriuretic peptides randomized controlled trial 1125 1129 5 03/08/23 20230401 NES 230401 BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower glucose, weight and blood pressure, and reduce cardiovascular and kidney outcomes in people with type 2 diabetes (T2D).[1], [2], [3] Although mechanisms for their effects remain unclear, small recent studies have reported that they may reduce natriuretic peptides.[4] B-type natriuretic peptide (BNP) and its inactive precursor N-terminal-pro BNP (NT-proBNP) were measured at baseline and follow-up in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial. GLP-1 receptor agonists, lixisentatide, natriuretic peptides, randomized controlled trial 2 Abbreviation: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; NT-proBNP, N terminal, pro-hormone B-type natriuretic peptide. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. [Extracted from the article]